Grants.gov Downtime Will Impact Application Due Dates in September

To facilitate a major technical upgrade to Grants.gov, the web system will undergo downtime from September 23 to September 29, 2022. In response, all NIH grant application due dates that fall on or between September 22 and September 30 will shift to October 3, 2022.

As noted in Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022, several procedures are dependent on an applicant’s intended receipt date and will be treated as follows:

• Continuous Submission—Eligible applications for the September 7, 2022 AIDS application due date may be submitted until October 3, 2022.
• Late Applications—The two-week window of consideration will be calculated based on the original due date.
• Viewing Window—The two-day period in which applicants can review a submitted application in eRA Commons will function as usual, beginning upon submission.
• FOA Expiration—For any FOA with a final due date and subsequent expiration date in the impacted period, Grants.gov will allow a grace period for submission even though the FOA will appear to have expired.

Remember, you are not required to apply after the scheduled downtime; consider submitting before September 22 if your targeted receipt date lands within the week of scheduled Grants.gov maintenance.

There are 14 funding opportunity announcements in which NIAID is participating that have receipt dates in the adjustment window. They are:

• PA-20-142, Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
• PA-20-162, Ruth L. Kirschstein NRSA Short-Term Institutional Research Training Grant (Parent T35)
• PAR-20-063, NIAID Resource-Related Research Projects (R24, Clinical Trial Not Allowed)
• PAR-20-089, Biomedical Data Repository (U24, Clinical Trials Not Allowed)  
• PAR-20-097, Biomedical Knowledgebase (U24, Clinical Trials Not Allowed)
• PAR-20-315, Limited Competition—Lasker Clinical Research Scholars Transition Award (R00, Clinical Trial Optional)
• PAR-21-038, Stephen I. Katz Early-Stage Investigator Research Project Grant (R01, Clinical Trial Not Allowed)
• PAR-21-173, Support for Research Excellence First Independent Research (SuRE-First) Award (R16, Clinical Trial Not Allowed)
• PAR-21-189, Medical Scientist Training Program (T32)
• PAR-21-356, Limited Competition—Research Resource for the National Swine Resource and Research Center (U42, Clinical Trial Not Allowed)
• PAR-22-056, Limited Competition—Research Resource for Human Organs and Tissues (U42, Clinical Trial Not Allowed)
• PAR-22-203, Point-of-Care Technologies Research Network—Technology Research and Development Centers (TRDC) (U54, Clinical Trial Optional)
• NOT-AI-20-044, NOSI—NIAID Priorities for Biomedical Knowledgebases and Repositories
• NOT-CA-22-063, Notice of Special Interest (NOSI)—Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy

Note that the text of these FOAs will not be edited to reflect the shift in submission deadlines. If you have specific questions, contact the NIAID scientific review officer listed in the corresponding FOA.